Asia Pacific Pregnancy Ovulation Testing Market Size

Asia Pacific Pregnancy Ovulation Testing Market Growth Projections and Opportunities

Pregnancy testing involves the identification of human Chorionic Gonadotropin (hCG) present in both urine and serum, detectable as early as 7 to 10 days after conception. Conversely, ovulation testing revolves around the detection of Luteinizing Hormone (LH) levels. The burgeoning awareness regarding pregnancy and ovulation testing has spurred marketers to introduce innovative and advanced products into the market. For example, in January 2016, Church & Dwight Co., Inc. unveiled the FIRST RESPONSE Pregnancy Pro Digital test along with App Access.

Several factors contribute to the upsurge in the pregnancy and ovulation testing market, including a decline in fertility rates, amplified promotional endeavors by marketers concerning ovulation tests, and the effortless accessibility of ovulation monitors on e-commerce platforms. Notably, in August 2013, Swiss Precision Diagnostics (SPD), under the Clearblue brand, witnessed a substantial surge in market demand owing to extensive advertising and campaigns.

However, certain impediments such as the lack of precision in available testing products and the elevated cost of ovulation monitors pose challenges, hindering the market's growth trajectory.

The Asia Pacific region's pregnancy and ovulation testing market are anticipated to experience a Compound Annual Growth Rate (CAGR) of 6.1% during the forecast period from 2018 to 2023.

In the preceding year of 2017, Japan led the market, capturing a share of 23.2%, closely followed by China and India, securing shares of 22.5% and 19.7%, respectively. Japan's growth is primarily attributed to the escalating demand for pregnancy testing within the region.

Segmentation of the Asia Pacific pregnancy and ovulation testing market is based on product type, mode of purchase, end-user, and region. Among the various product types, pregnancy testing (hCG detection) held the lion's share, accounting for 81.6% in 2017, boasting a market value of USD 170.91 million. This segment is projected to register a CAGR of 5.95% during the forecast period.

Regarding the mode of purchase, non-prescription or Over-The-Counter (OTC) testing dominated with a commanding market share of 68.2% in 2017, valued at USD 142.79 million. Projections indicate that it will witness the highest CAGR of 6.0%.

In terms of end-users, hospitals and clinics constituted the largest market share, holding 55.6% in 2017, with a market value of USD 116.31 million. It is forecasted to register the highest CAGR of 5.78%.